Zobrazeno 1 - 10 of 65 pro vyhledávání: '"Toshio Tabei"'
1
[A Case of Advanced Breast Cancer with Hypercalcemia and No Bone Metastasis Treated with Multidisciplinary Therapy]
Autor: Kana, Yamasaki, Takashi, Nakakuma, Soichiro, Ueno, Takuma, Yuda, Masashi, Tsuru, Toshio, Tabei
Publikováno v: Gan to kagaku ryoho. Cancerchemotherapy. 47(13)
A 37-year-old woman presented with general malaise, anorexia, and nausea. She was hypercalcemic and had an 8-cm- diameter mass in her left breast. Histopathological diagnosis was invasive breast cancer(T3N0M1). She had multiple lung metastases and pl
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c41511561f42dc2663f14991151fc7a1
https://pubmed.ncbi.nlm.nih.gov/33468890
Zobrazit plný text záznamu
2
[A Case of Recurrent Breast Cancer with Contralateral Axillary Node Recurrence Cured after Mastectomy for Ipsilateral Breast Tumor Recurrence]
Autor: Takashi, Nakakuma, Kana, Takahashi, Souichirou, Ueno, Toshio, Tabei, Tadahiro, Inada, Yasushi, Kondou, Yoshimasa, Kosaka, Norihiko, Sengoku
Publikováno v: Gan to kagaku ryoho. Cancerchemotherapy. 46(13)
A 65-year-old woman was treated with breast-conserving therapy for dissection of the left breast and axillary lymph nodes. Histopathological diagnosis was invasive breast cancer(scirrhous), T1cN2M0, stageⅡB, ER+/PgR+/HER2-. Approximately 4 years la
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::26d5fe86ff90ffbc070887d06be88ed6
https://pubmed.ncbi.nlm.nih.gov/32157045
Zobrazit plný text záznamu
4
A multicenter prospective study to evaluate bone fracture related to adjuvant anastrozole in Japanese postmenopausal women with breast cancer: two-year interim analysis of Saitama Breast Cancer Clinical Study Group (SBCCSG-06)
Autor: Makoto Kojima, Hiroyuki Takei, Hideki Takeuchi, Takashi Yoshida, Toshio Tabei, Kazushige Futsuhara, Toshihiro Kai
Publikováno v: International Journal of Clinical Oncology. 19:68-73
Because of its superior efficacy to tamoxifen, anastrozole has been widely used in Japan as an adjuvant treatment for postmenopausal, hormone-responsive breast cancer patients. However, anastrozole may affect bone in Japanese patients similar to its
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0ac643eb863cb857ad1d8d4f5d25343
https://doi.org/10.1007/s10147-012-0512-7
Zobrazit plný text záznamu
5
Pathological tumor response to neoadjuvant chemotherapy using anthracycline and taxanes in patients with triple-negative breast cancer
Autor: Hiroyuki Takei, Masafumi Kurosumi, Yasuhito Kobayashi, Toshio Tabei, Kenichi Inoue, Hanako Oba, Kaori Sakuma, Tetsunari Oyama
Publikováno v: Experimental and Therapeutic Medicine. 2:257-264
Although triple-negative breast cancer (TNBC) is associated with a poor prognosis, recent reports have indicated that a higher proportion of TNBC patients shows a pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) than is the case
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::deca401db9ec6c3a62f12b3961f19f5a
https://doi.org/10.3892/etm.2011.212
Zobrazit plný text záznamu
6
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
Autor: Kenjiro Aogi, Soo-Chin Lee, Mei-Ching Liu, Miguel Martin, Jean-Marc Ferrero, Laurence Vanlemmens, Hiroji Iwata, Toshio Tabei, Carlos H. Barrios, Kenneth A. Kern, Nadia Harbeck, Ke-Ke Zhang, Marla J. Brickman, Roberto Lugo-Quintana, Xavier Pivot
Publikováno v: Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, 2010, 121 (1), pp.121-31. ⟨10.1007/s10549-010-0788-0⟩
Breast Cancer Research and Treatment, Springer Verlag, 2010, 121 (1), pp.121-31. ⟨10.1007/s10549-010-0788-0⟩
International audience; This multicenter, randomized, open-label phase III trial (planned enrollment: 700 patients) was conducted to test the hypothesis that single-agent sunitinib improves progression-free survival (PFS) compared with capecitabine a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb762e34005f747cf404b4839e7794ba
https://doi.org/10.1007/s10549-010-0788-0
Zobrazit plný text záznamu
7
Axillary lymph node dissection can be avoided in women with breast cancer with intraoperative, false-negative sentinel lymph node biopsies
Autor: Tomoko Kazumoto, Yuji Hayashi, Jun-ichi Saitoh, Katsunori Tozuka, Yoshihiro Saito, Hiroyuki Takei, Jun Ninomiya, Toshio Tabei, Masafumi Kurosumi, Kenichi Inoue, Hanako Oba, Shigenori Nagai, Takashi Yoshida, Yuko Ishikawa
Publikováno v: Breast Cancer. 17:9-16
It is currently unclear which patients with breast cancer with sentinel lymph node (SLN) metastases do not need axillary lymph node dissection (ALND). A cohort of 1,132 women who had unilateral invasive breast cancer with clinically negative nodes or
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f314567054dcebc65aa195e09dcf1eda
https://doi.org/10.1007/s12282-009-0154-4
Zobrazit plný text záznamu
8
Ipsilateral breast tumor relapse after breast conserving surgery in women with breast cancer
Autor: Katsunori Tozuka, Yuko Ishikawa, Yuji Hayashi, Hiroyuki Takei, Takashi Yoshida, Jun Ninomiya, Kenichi Inoue, Masafumi Kurosumi, Hanako Oba, Toshio Tabei
Publikováno v: The Breast. 18:238-243
Ipsilateral breast tumor relapse (IBTR) is a potentially a significant problem after breast conserving surgery (BCS). With a median follow-up period of 64.7 months, IBTR occurred as a first relapse in 67 (3.0%) of a total of 2243 patients and distant
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d537ea21ce51203e6a858e9b8b9ac31
https://doi.org/10.1016/j.breast.2009.06.001
Zobrazit plný text záznamu
9
Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer
Autor: Toshio Tabei, Kazushige Toyama, Masataka Yoshimoto, Shigeto Miura, Eisei Shin, Tadashi Nomizu, Mikihiro Kusama, Shinzaburo Noguchi, Noboru Horikoshi, Morihiko Kimura, Kenjiro Aogi, N. Yoshimura
Publikováno v: Breast Cancer. 17:233-240
A multicenter, phase II study was conducted to evaluate the efficacy and safety of the Japanese intermittent 4-week regimen of capecitabine in patients with advanced/metastatic breast cancer.Fifty patients who had received no more than one prior chem
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce0dbe093ca19911b1f2a30a8e5a505c
https://doi.org/10.1007/s12282-009-0137-5
Zobrazit plný text záznamu
10
Evaluation of the safety and tolerability of oral TAS-108 in postmenopausal patients with metastatic breast cancer
Autor: H. Inaji, Shinzaburo Noguchi, Kenjiro Aogi, Tadashi Ikeda, Toshio Tabei, Toshiaki Saeki
Publikováno v: Annals of Oncology. 20:868-873
Background The potential of TAS-108 for the treatment of breast cancer has been shown by preclinical studies. We therefore investigated the safe dosage, tolerability, and effectiveness on hormone levels and bone metabolism markers and the pharmacokin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a17645e75043165553a7cf1d2d58973
https://doi.org/10.1093/annonc/mdn714
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje